https://www.neurologylive.com/view/growing-trofinetide-long-term-profile-first-approved-rett-syndrome-therapy-ponni-subbiah
0
0
12/13/23 at 8:08pm
Organization
Neurologylive.com
The senior vice president, global head of medical affairs, and chief medical officer at Acadia Pharmaceutical, provided an overview of LILAC-2, a long-term, open-label study assessing the treatment benefits of trofinetide (Daybue). [WATCH TIME: 6 minutes]
Create an account
or login to join the discussion